• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Samaritan In-Licenses Greece & Cyprus Marketing Rights for Amphocil From Three Rivers Pharmaceuticals

Posted on: Wednesday, 14 December 2005, 06:00 CST

Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today its European subsidiary, Samaritan Europe has entered into an exclusive distribution agreement with Three Rivers Pharmaceuticals for the marketing and sales of Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) in Greece and Cyprus. Amphocil is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients.

"Three Rivers Pharmaceuticals is very pleased to be partnering with Samaritan Europe," stated Donald J. Kerrish, RPh, President and CEO of Three Rivers Pharmaceuticals. "This distribution agreement is a welcome addition to our existing partnerships in Europe, and it demonstrates Three Rivers commitment to grow globally."

Dr. Greeson, CEO of Samaritan stated, "We are thrilled with the Three Rivers Pharmaceuticals agreement as it allows Samaritan Europe to swiftly implement our marketing and sales arm in Greece, Cyprus and other designated countries in Eastern Europe." Dr. Greeson further stated, "We have identified, a niche within a niche, specialty products within Eastern Europe. While the majority of sales for pharmaceuticals come from the US and the big five European markets; and aside from the majors, marketing and sales is normally out-licensed to local sales forces in Eastern Europe, such as Samaritan Europe. Additionally, Amphocil is a specialty niche product targeted for immuno-compromised patients; marketing to HIV physicians compliments Samaritan's focused indications."

About Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a privately owned company located in Cranberry Township, PA. Three Rivers Pharmaceuticals' mission is to develop and market specialty prescription drugs for diseases that have a significant national and worldwide impact. The company is dedicated to providing public education, disease state management programs, and improving patient access to high quality, lower cost pharmaceutical products. For additional information about Three Rivers Pharmaceuticals, please visit www.3riverspharma.com

Samaritan Pharmaceuticals: "We LIV....to Save Lives."

Samaritan Pharmaceuticals is a drug development company driven to commercialize innovative drugs. Samaritan, in collaboration with Georgetown University, is advancing 8 promising compounds, out of its pipeline of 250 possible drug candidates; all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com.

Disclaimer

The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.

Source: Business Wire

More News in this Category